These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9724020)

  • 1. Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression.
    Lee H; Struman I; Clapp C; Martial J; Weiner RI
    Endocrinology; 1998 Sep; 139(9):3696-703. PubMed ID: 9724020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin.
    Bajou K; Herkenne S; Thijssen VL; D'Amico S; Nguyen NQ; Bouché A; Tabruyn S; Srahna M; Carabin JY; Nivelles O; Paques C; Cornelissen I; Lion M; Noel A; Gils A; Vinckier S; Declerck PJ; Griffioen AW; Dewerchin M; Martial JA; Carmeliet P; Struman I
    Nat Med; 2014 Jul; 20(7):741-7. PubMed ID: 24929950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis.
    Clapp C; Martial JA; Guzman RC; Rentier-Delure F; Weiner RI
    Endocrinology; 1993 Sep; 133(3):1292-9. PubMed ID: 7689950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells.
    Ferrara N; Clapp C; Weiner R
    Endocrinology; 1991 Aug; 129(2):896-900. PubMed ID: 1855480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation.
    Gonzalez C; Corbacho AM; Eiserich JP; Garcia C; Lopez-Barrera F; Morales-Tlalpan V; Barajas-Espinosa A; Diaz-Muñoz M; Rubio R; Lin SH; Martinez de la Escalera G; Clapp C
    Endocrinology; 2004 Dec; 145(12):5714-22. PubMed ID: 15358675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator inhibitor-1 expression by brain microvessel endothelial cells is inhibited by elevated glucose.
    Kollros PR; Konkle BA; Ambarian AP; Henrikson P
    J Neurochem; 1994 Sep; 63(3):903-9. PubMed ID: 7519664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
    Allan EH; Martin TJ
    J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases.
    Kim MH
    J Cell Biochem; 2003 Jun; 89(3):529-38. PubMed ID: 12761886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
    Tanabe T
    Hiroshima J Med Sci; 2000 Mar; 49(1):67-72. PubMed ID: 10824459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation.
    Martini JF; Piot C; Humeau LM; Struman I; Martial JA; Weiner RI
    Mol Endocrinol; 2000 Oct; 14(10):1536-49. PubMed ID: 11043570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
    Gutierrez LS; Schulman A; Brito-Robinson T; Noria F; Ploplis VA; Castellino FJ
    Cancer Res; 2000 Oct; 60(20):5839-47. PubMed ID: 11059781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity.
    Odekon LE; Sato Y; Rifkin DB
    J Cell Physiol; 1992 Feb; 150(2):258-63. PubMed ID: 1734031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.
    Feng Q; Liu Y; Liu K; Byrne S; Liu G; Wang X; Li Z; Ockleford CD
    Placenta; 2000; 21(2-3):184-93. PubMed ID: 10736241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain-derived neurotrophic factor inducing angiogenesis through modulation of matrix-degrading proteases.
    Sun CY; Hu Y; Wang HF; He WJ; Wang YD; Wu T
    Chin Med J (Engl); 2006 Apr; 119(7):589-95. PubMed ID: 16620701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
    FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 by grape seed proanthocyanidin extract.
    Sandra D; Radha M; Harishkumar M; Yuichi N; Sayuri O; Masugi M
    Phytomedicine; 2010 Jan; 17(1):42-6. PubMed ID: 19640694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.